Filamentous Fungi Genome Integration Patents: Leaders & Trends 2026
Filamentous Fungi Genome Integration Patents: Who Holds the Ground and Where It's Open
43.3% concentration. The five leading assignees hold 969 of the 2,238 records in scope — a tight cluster around a small set of industrial enzyme and biotech firms. Filing rose to a peak of 61 records in 2017, then eased. The 2021-2024 window — the last span with figures reliable enough to compare — moved from 39 to 21 records, a 46% decline. Readers should treat 2025 and 2026 as incomplete rather than as continued contraction.
- 1NOVOZYMES AS312
- 2NOVOZYMES INC228
- 3DSM IP ASSETS BV212
- 4NOVOZYMES BIOTECH INC125
- 5GENECOR INC92
See the full filamentous fungi genome integration analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in filamentous fungi genome integration?
One assignee leads clearly with 312 of the 2,238 records in scope, compared with 92 at fifth place and 41 at tenth. The leading names are longstanding industrial enzyme and fermentation companies rather than recent entrants. That gap between first place and the rest suggests an early, well-defended position rather than an open contest among several comparably sized filers.
Is patent filing in this field growing or shrinking?
Filing peaked in 2017 at 61 records and has trended down since; the 2021-to-2024 span, the most recent period with reliable complete-year data, fell 46% from 39 to 21 records. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by about 18 months, so they should not yet be read as continued decline. The honest summary is that the field has cooled from a mid-2010s peak, with the very latest trend still unresolved.
What does EP2172557B1 actually cover?
EP2172557B1, held by DSM IP Assets B.V. and granted in 2018, covers methods for increasing the efficiency of targeted polynucleotide integration in filamentous fungal cells by steering the cell’s repair pathway toward homologous recombination (HR) and away from non-homologous recombination (NHR). It also covers mutant fungal strains engineered to have this altered HR/NHR balance relative to a parent strain. Anyone working on directed integration efficiency in filamentous fungi should check their approach against this claim scope specifically, since it targets the pathway-steering mechanism rather than a single gene target.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Filamentous Fungi Genome Integration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.